Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

Stock Information for Applied DNA Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Applied DNA Sciences Inc.

Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.